Eisai Submits NDA for Dotinurad (Uloric) in China for the Treatment of Gout and Hyperuricemia

Eisai China Official WeChat Announcement: On January 22, the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) disclosed that the marketing application for Dotinurad tablets, submitted by Eisai under Registration Category 5.1, has been accepted. Dotinurad tablets (Dotinurad, trade name: Uloric) are a uricosuric drug that was previously launched in Japan in 2020 for the treatment of hyperuricemia and gout.